Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Neumora Therapeutics (Nasdaq: NMRA) will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026 at 10:15 a.m. ET. A live webcast will stream on the company's events and presentations page, with a replay archived for up to 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – NMRA
In the Apr 6 session, NMRA gained 6.00%, reflecting a notable positive market reaction. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 30 | Earnings results | Neutral | -17.2% | Reported Q4 and 2025 results plus pipeline and cash runway update. |
| Mar 16 | Earnings date | Neutral | +1.0% | Announced timing and access details for Q4 and 2025 earnings call. |
| Feb 04 | Conference participation | Neutral | -1.0% | Planned fireside chat at Guggenheim Emerging Outlook: Biotech Summit 2026. |
| Jan 05 | Pipeline strategy update | Positive | -1.5% | Outlined 2026 strategy, KOASTAL-2/3 expansion and NMRA-215 Phase 1 plans. |
| Jan 05 | Clinical trial results | Positive | -1.5% | Reported positive NMRA-511 Phase 1b signal-seeking data in AD agitation. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical and pipeline updates around NMRA-511 and broader 2026 strategy saw modest negative moves near -1.5%, while neutral scheduling or conference items had relatively small reactions.
Over the last few months, Neumora has focused on advancing its late-stage and early pipeline while maintaining a solid cash position. On Jan 5, 2026, it reported positive Phase 1b results for NMRA-511 in Alzheimer’s agitation and separately outlined its 2026 pipeline strategy, including KOASTAL-2/3 readouts expected in Q2 2026. An earnings date announcement on Mar 16, 2026 and participation in a Guggenheim summit on Feb 11, 2026 were largely scheduling updates. On Mar 30, 2026, Neumora reported Q4 and full-year 2025 results, highlighting cash of $182.5M and runway into Q3 2027.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 10:15 a.m. ET.
A live webcast of the fireside chat will be available on the events and presentations section of the Company’s website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.
About Neumora
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the greatest medical challenges of our generation by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients.
Neumora Contact:
Helen Rubinstein
617-402-5700
Helen.Rubinstein@neumoratx.com
